Qurient Co. Ltd Total Liabilities

Latest as of June 2026: ₩23.76 Billion KRW ≈ $16.10 Million USD

Qurient Co. Ltd total liabilities. Based on the latest financial reports, Qurient Co. Ltd (115180) has total liabilities worth ₩23.76 Billion KRW (≈ $16.10 Million USD) as of June 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check 115180 asset liquidity ratio to evaluate the company's liquid asset resilience ratio.

Total Liabilities of Qurient Co. Ltd (2014–2025)

Total liabilities of Qurient Co. Ltd from 2014 to 2025. This chart illustrates how Qurient Co. Ltd's total liabilities have evolved over time, based on quarterly financial data. Explore Qurient Co. Ltd strategic investment ratio to see how much of total assets are deployed in long-term investments.

Qurient Co. Ltd Competitors by Total Liabilities

The table below lists competitors of Qurient Co. Ltd ranked by their total liabilities.

Company Country Total Liabilities
ZJBC Information Technology Co Ltd
SHE:000889
China CN¥885.66 Million
Jiangxi Synergy Pharmaceutical Co Ltd
SHE:300636
China CN¥927.61 Million
Sichuan Kexin Mechanic Electric
SHE:300092
China CN¥548.79 Million
init innovation in traffic systems SE
F:IXX
Germany €183.70 Million
Lanner Electronics
TWO:6245
Taiwan NT$2.89 Billion
GHCL Limited
NSE:GHCL
India Rs7.48 Billion
First Copper Technology Co Ltd
TW:2009
Taiwan NT$2.42 Billion
Editas Medicine Inc
NASDAQ:EDIT
USA $132.08 Million

Liability Composition Analysis (2014–2025)

This chart breaks down Qurient Co. Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see 115180 asset base.

Liquidity & Leverage Metrics

Qurient Co. Ltd Total Liabilities Ratios Explained

Qurient Co. Ltd total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.

Metric Value Description
Current Ratio 10.35 Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio N/A More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio N/A Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity 1.38 Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets 0.52 Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how Qurient Co. Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for Qurient Co. Ltd (2014–2025)

The table below shows the annual total liabilities of Qurient Co. Ltd from 2014 to 2025.

Year Total Liabilities Change
2025-12-31 ₩22.80 Billion
≈ $15.45 Million
+185.93%
2024-12-31 ₩7.97 Billion
≈ $5.40 Million
+35.53%
2023-12-31 ₩5.88 Billion
≈ $3.99 Million
+79.65%
2022-12-31 ₩3.28 Billion
≈ $2.22 Million
-7.61%
2021-12-31 ₩3.55 Billion
≈ $2.40 Million
-16.46%
2020-12-31 ₩4.24 Billion
≈ $2.88 Million
+35.36%
2019-12-31 ₩3.14 Billion
≈ $2.12 Million
-17.30%
2018-12-31 ₩3.79 Billion
≈ $2.57 Million
+230.89%
2017-12-31 ₩1.15 Billion
≈ $776.40K
-39.40%
2016-12-31 ₩1.89 Billion
≈ $1.28 Million
+96.17%
2015-12-31 ₩963.76 Million
≈ $653.12K
-97.09%
2014-12-31 ₩33.11 Billion
≈ $22.44 Million
--

About Qurient Co. Ltd

KQ:115180 Korea Biotechnology
Market Cap
$400.00 Million
₩590.25 Billion KRW
Market Cap Rank
#13038 Global
#373 in Korea
Share Price
₩15840.00
Change (1 day)
-5.77%
52-Week Range
₩14850.00 - ₩50900.00
All Time High
₩50900.00
About

Qurient Co., Ltd., a biotech company, engages in the research and development of drugs to address unmet medical needs in Korea and internationally. The company's pipeline products include Q301, a topical 5LO inhibitor, which is in Phase II clinical trial for the treatment of atopic dermatitis; and Telacebec (Q203), Cyt bc1 Inhibitor, that is in Phase II to treat Mycobacterial Infections, such as … Read more